The COVID-19 has been a worldwide pandemic and it wants for research associated to impact on individuals’s demand for insurance throughout the pandemic which is a vital solution to switch threat. However, there’s a lack of analysis linking COVID-19 and other people’s demand for insurance. The goal of this paper is to analyze the impact of COVID-19 pandemic on issuance demand, utilizing knowledge overlaying 241 cities on confirmed COVID-19 circumstances and insurance firm income in China.
The empirical outcomes present that extra confirmed COVID-19 circumstances are related to better per capita insurance income and the outcomes are strong when contemplating endogeneity concern.
Economically, the per capita insurance income will increase by 0.896 Yuan for every extra confirmed case. In phrases of insurance kind, the best elevated insurance income is for all times insurance, adopted by well being insurance. We additional think about the heterogeneity of areas and discover that the impact of COVID-19 on insurance income solely exists in areas with worse medical therapy circumstances or larger medical burden.
Acquired ABC-transporter overexpression in most cancers cells: transcriptional induction or Darwinian choice?
Acquired multidrug resistance (MDR) in tumor illnesses has repeatedly been related to overexpression of ATP-binding cassette transporters (ABC-transporters) corresponding to P-glycoprotein. Both in vitro and in vivo knowledge counsel that these efflux transporters may cause MDR, albeit its precise relevance for medical chemotherapy unresponsiveness stays unsure. The overexpression can experimentally be achieved by publicity of tumor cells to cytotoxic medicine.
For simplification, the drug-mediated transporter overexpression will be attributed to 2 reverse mechanisms: First, elevated transcription of ABC-transporter genes mediated by nuclear receptors sensing the respective compound. Second, Darwinian choice of sub-clones intrinsically overexpressing drug transporters being succesful of extruding the respective drug. To date, there isn’t a particular knowledge indicating which mechanism actually applies or whether or not there are circumstances selling both mode of motion.
This evaluation summarizes experimental proof for each theories, suggests an algorithm discriminating between these two modes, and at last factors out future experimental approaches of analysis to reply this primary query in most cancers pharmacology.
Facilitating Growth Mixture Model Convergence in Preventive Interventions
Growth combination fashions (GMMs) are utilized to intervention research with repeated measures to discover heterogeneity in the intervention impact. However, conventional GMMs are recognized to be troublesome to estimate, particularly at pattern sizes frequent in single-center interventions. Common methods to coerce GMMs to converge contain put up hoc changes to the mannequin, notably constraining covariance parameters to equality throughout courses.
Methodological research have proven that though convergence is improved with put up hoc changes, they embed extra tenuous assumptions into the mannequin that may adversely impact key points of the mannequin corresponding to quantity of courses extracted and the estimated progress trajectories in every class. To facilitate convergence with out put up hoc changes, this paper critiques the current literature on covariance sample combination fashions, which method GMMs from a marginal modeling custom fairly than the random impact modeling custom utilized by conventional GMMs.
We talk about how the marginal modeling custom can keep away from complexities in estimation encountered by GMMs that function random results, and we use knowledge from a life-style intervention for rising insulin sensitivity (a threat issue for kind 2 diabetes) amongst 90 Latino adolescents with weight problems to reveal our level. Specifically, GMMs that includes random effects-even with put up hoc adjustments-fail to converge as a result of estimation errors, whereas covariance sample combination fashions following the marginal mannequin custom encounter no points with estimation whereas sustaining the capability to reply all the analysis questions.
Effect of storage time on the urine protein: creatinine ratio in alkaline ovine urine
The urine protein:creatinine (UPC) ratio is taken into account the reference methodology to evaluate proteinuria. Its diagnostic worth in ovine drugs wants additional elucidation. In inhabitants monitoring and/or for analysis functions, it’s handy to gather many samples concurrently and retailer them for later evaluation. However, analyte stability knowledge are required to make sure dependable outcomes. We used 15 of 90 urine samples collected from sheep to evaluate the impact of storage time on the UPC ratio. After centrifugation, the supernatant of every pattern was divided into 6 aliquots.
Urine protein and creatinine concentrations had been decided instantly in a single aliquot utilizing the pyrogallol purple and a modified Jaffè methodology, respectively. The different aliquots had been saved at -18°C. Based on the absence of energetic sediment, alkaline urine pH, and UPC ratio ≥ 0.2, we included 15 samples in our research.
The UPC ratio was decided in the saved aliquots 2, 7, 14, 21, and 60 d after assortment. The knowledge had been analyzed with univariate ANOVA. No important distinction was noticed in the urinary concentrations of protein, creatinine, and the UPC ratio (0.8 ± 0.84 in typical models and 0.09 ± 0.095 in SI models) amongst totally different instances (p > 0.05). The UPC ratio remained steady for two mo in ovine urine samples saved at -18°C.
Multimodal Disentangled Variational Autoencoder with Game Theoretic Interpretability for Glioma grading
Effective fusion of multimodal magnetic resonance imaging (MRI) is of nice significance to spice up the accuracy of glioma grading because of the complementary info supplied by totally different imaging modalities. However, how you can extract the frequent and distinctive info from MRI to realize complementarity remains to be an open downside in info fusion analysis. In this research, we suggest a deep neural community mannequin termed as multimodal disentangled variational autoencoder (MMD-VAE) for glioma grading based mostly on radiomics options extracted from preoperative multimodal MRI photographs.
Specifically, the radiomics options are quantized and extracted from the area of curiosity for every modality. Then, the latent representations of variational autoencoder for these options are disentangled into frequent and distinctive representations to acquire the shared and complementary knowledge amongst modalities. Afterward, cross-modality reconstruction loss and common-distinctive loss are designed to make sure the effectiveness of the disentangled representations.
Finally, the disentangled frequent and distinctive representations are fused to foretell the glioma grades, and SHapley Additive exPlanations (SHAP) is adopted to quantitatively interpret and analyze the contribution of the essential options to grading.
 FGF21 Polyclonal Antibody |
|
ES9145-50ul |
ELK Biotech |
50ul |
EUR 207 |
|
Description: A Rabbit Polyclonal antibody against FGF21 from Human. This antibody is tested and validated for WB, ELISA, WB, ELISA |
FGF21 Polyclonal Antibody |
|
ABP58547-003ml |
Abbkine |
0.03ml |
EUR 158 |
|
|
|
Description: A polyclonal antibody for detection of FGF21 from Human. This FGF21 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human FGF21 protein at amino acid sequence of 90-170 |
FGF21 Polyclonal Antibody |
|
ABP58547-01ml |
Abbkine |
0.1ml |
EUR 289 |
|
|
|
Description: A polyclonal antibody for detection of FGF21 from Human. This FGF21 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human FGF21 protein at amino acid sequence of 90-170 |
FGF21 Polyclonal Antibody |
|
ABP58547-02ml |
Abbkine |
0.2ml |
EUR 414 |
|
|
|
Description: A polyclonal antibody for detection of FGF21 from Human. This FGF21 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human FGF21 protein at amino acid sequence of 90-170 |
FGF21 Polyclonal Antibody |
|
A52640 |
EpiGentek |
100 µg |
EUR 570.55 |
|
Description: reagents widely cited |
 Fgf21 Polyclonal Antibody |
|
A62586 |
EpiGentek |
100 µg |
EUR 570.55 |
|
Description: fast delivery possible |
 Anti-FGF21 Biotinylated Antibody |
|
A00802-Biotin |
BosterBio |
50ug/vial |
EUR 294 |
 anti-FGF21 |
|
YF-PA18287 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to FGF21 |
anti-FGF21 |
|
YF-PA18288 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to FGF21 |
anti-FGF21 |
|
YF-PA18289 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to FGF21 |
 FGF21 Antibody |
|
1-CSB-PA290047 |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against FGF21. Recognizes FGF21 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100 |
 Fgf21 Antibody |
|
1-CSB-PA008627LA01MO |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against Fgf21. Recognizes Fgf21 from Mouse. This antibody is Unconjugated. Tested in the following application: ELISA |
FGF21 Antibody |
|
1-CSB-PA06404A0Rb |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against FGF21. Recognizes FGF21 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200 |
FGF21 Antibody |
|
1-CSB-PA876229 |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against FGF21. Recognizes FGF21 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
FGF21 Antibody |
|
36478-100ul |
SAB |
100ul |
EUR 252 |
FGF21 Antibody |
|
49516-100ul |
SAB |
100ul |
EUR 333 |
FGF21 Antibody |
|
49516-50ul |
SAB |
50ul |
EUR 239 |
FGF21 Antibody |
|
DF8947 |
Affbiotech |
200ul |
EUR 304 |
|
Description: FGF21 Antibody detects endogenous levels of total FGF21. |
 Anti-FGF21 Rabbit Monoclonal Antibody |
|
M00802 |
BosterBio |
100ug/vial |
EUR 397 |
|
Description: Anti-FGF21 Rabbit Monoclonal Antibodytested for IHC, WB in Human, Mouse, Rat |
 polyclonal antibody) Myeloid/lymphoid or mixed-lineage leukemia translocated to 10 (MLLT10) polyclonal antibody |
|
ABP-PAB-10850 |
Allele Biotech |
100 ug |
Ask for price |
|
|
 polyclonal antibody) Myeloid/lymphoid or mixed-lineage leukemia translocated to 1 (MLLT1) polyclonal antibody |
|
ABP-PAB-10851 |
Allele Biotech |
100 ug |
Ask for price |
|
|
 polyclonal antibody) Myeloid/lymphoid or mixed-lineage leukemia translocated to 2 (MLLT2) polyclonal antibody |
|
ABP-PAB-10852 |
Allele Biotech |
100 ug |
Ask for price |
|
|
 polyclonal antibody) Myeloid/lymphoid or mixed-lineage leukemia translocated to 3 (MLLT3) polyclonal antibody |
|
ABP-PAB-10853 |
Allele Biotech |
100 ug |
Ask for price |
|
|
 polyclonal antibody) Myeloid/lymphoid or mixed-lineage leukemia translocated to 4 (MLLT4) polyclonal antibody |
|
ABP-PAB-10854 |
Allele Biotech |
100 ug |
Ask for price |
|
|
 polyclonal antibody) Myeloid/lymphoid or mixed-lineage leukemia translocated to 6 (MLLT6) polyclonal antibody |
|
ABP-PAB-10855 |
Allele Biotech |
100 ug |
Ask for price |
|
|
 polyclonal antibody) Myeloid/lymphoid or mixed-lineage leukemia translocated to 7 (MLLT7) polyclonal antibody |
|
ABP-PAB-10856 |
Allele Biotech |
100 ug |
Ask for price |
|
|
 FGF21 Polyclonal Antibody, Biotin Conjugated |
|
A52637 |
EpiGentek |
100 µg |
EUR 570.55 |
|
Description: fast delivery possible |
 FGF21 Polyclonal Antibody, FITC Conjugated |
|
A52638 |
EpiGentek |
100 µg |
EUR 570.55 |
|
Description: reagents widely cited |
 FGF21 Polyclonal Antibody, HRP Conjugated |
|
A52639 |
EpiGentek |
100 µg |
EUR 570.55 |
|
Description: Ask the seller for details |
 Fgf21 Polyclonal Antibody, HRP Conjugated |
|
A62587 |
EpiGentek |
100 µg |
EUR 570.55 |
|
Description: reagents widely cited |
 Fgf21 Polyclonal Antibody, FITC Conjugated |
|
A62588 |
EpiGentek |
100 µg |
EUR 570.55 |
|
Description: Ask the seller for details |
 Fgf21 Polyclonal Antibody, Biotin Conjugated |
|
A62589 |
EpiGentek |
100 µg |
EUR 570.55 |
|
Description: The best epigenetics products |
 OR Antibody |
|
20-abx217389 |
Abbexa |
|
|
|
|
OR Antibody |
|
44609-100ul |
SAB |
100ul |
EUR 252 |
OR Antibody |
|
44609-50ul |
SAB |
50ul |
EUR 187 |
OR Antibody |
|
DF10250 |
Affbiotech |
200ul |
EUR 304 |
|
Description: OR Antibody detects endogenous levels of total OR. |
 Polyclonal Goat anti-GST α-form |
|
GST-ANTI-1 |
Detroit R&D |
50 uL |
EUR 280 |
 Polyclonal Goat anti-GST μ-form |
|
GST-ANTI-2 |
Detroit R&D |
50 uL |
EUR 280 |
 Polyclonal Goat anti-GST p-form |
|
GST-ANTI-3 |
Detroit R&D |
50 uL |
EUR 280 |
) Anti-FGF21 (2F11) |
|
YF-MA11430 |
Abfrontier |
100 ug |
EUR 363 |
|
Description: Mouse monoclonal to FGF21 |
) Anti-FGF21 (1A8) |
|
YF-MA11431 |
Abfrontier |
100 ug |
EUR 363 |
|
Description: Mouse monoclonal to FGF21 |
) Anti-FGF21 (3G10) |
|
YF-MA11432 |
Abfrontier |
100 ug |
EUR 363 |
|
Description: Mouse monoclonal to FGF21 |
) Anti-FGF21 (3A6) |
|
YF-MA11433 |
Abfrontier |
100 ug |
EUR 363 |
|
Description: Mouse monoclonal to FGF21 |
) Anti-FGF21 (3E8) |
|
YF-MA11434 |
Abfrontier |
100 ug |
EUR 363 |
|
Description: Mouse monoclonal to FGF21 |
) Anti-FGF21 (3E20) |
|
YF-MA20531 |
Abfrontier |
200 ul |
EUR 363 |
|
Description: Mouse monoclonal to FGF21 |
 FGF21 Conjugated Antibody |
|
C36478 |
SAB |
100ul |
EUR 397 |
FGF21 Conjugated Antibody |
|
C49516 |
SAB |
100ul |
EUR 397 |
 ELISA Kit) Human Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RD-FGF21-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 339 |
Human Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RD-FGF21-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 463 |
 ELISA Kit) Mouse Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RD-FGF21-Mu-48Tests |
Reddot Biotech |
48 Tests |
EUR 472 |
Mouse Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RD-FGF21-Mu-96Tests |
Reddot Biotech |
96 Tests |
EUR 653 |
 ELISA Kit) Porcine Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RD-FGF21-p-48Tests |
Reddot Biotech |
48 Tests |
EUR 545 |
Porcine Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RD-FGF21-p-96Tests |
Reddot Biotech |
96 Tests |
EUR 757 |
 ELISA Kit) Rat Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RD-FGF21-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 496 |
Rat Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RD-FGF21-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 688 |
Human Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
DLR-FGF21-Hu-48T |
DL Develop |
48T |
EUR 355 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Fibroblast Growth Factor 21 (FGF21) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Human Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
DLR-FGF21-Hu-96T |
DL Develop |
96T |
EUR 451 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Fibroblast Growth Factor 21 (FGF21) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Mouse Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
DLR-FGF21-Mu-48T |
DL Develop |
48T |
EUR 474 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Fibroblast Growth Factor 21 (FGF21) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Mouse Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
DLR-FGF21-Mu-96T |
DL Develop |
96T |
EUR 614 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Fibroblast Growth Factor 21 (FGF21) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Porcine Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
DLR-FGF21-p-48T |
DL Develop |
48T |
EUR 538 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Fibroblast Growth Factor 21 (FGF21) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Porcine Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
DLR-FGF21-p-96T |
DL Develop |
96T |
EUR 703 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Fibroblast Growth Factor 21 (FGF21) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Rat Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
DLR-FGF21-Ra-48T |
DL Develop |
48T |
EUR 495 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Fibroblast Growth Factor 21 (FGF21) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Rat Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
DLR-FGF21-Ra-96T |
DL Develop |
96T |
EUR 644 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Fibroblast Growth Factor 21 (FGF21) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Human Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RDR-FGF21-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 353 |
Human Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RDR-FGF21-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 483 |
Mouse Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RDR-FGF21-Mu-48Tests |
Reddot Biotech |
48 Tests |
EUR 493 |
Mouse Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RDR-FGF21-Mu-96Tests |
Reddot Biotech |
96 Tests |
EUR 683 |
Porcine Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RDR-FGF21-p-48Tests |
Reddot Biotech |
48 Tests |
EUR 570 |
Porcine Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RDR-FGF21-p-96Tests |
Reddot Biotech |
96 Tests |
EUR 793 |
Rat Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RDR-FGF21-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 519 |
Rat Fibroblast Growth Factor 21 (FGF21) ELISA Kit |
|
RDR-FGF21-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 720 |
 OR Conjugated Antibody |
|
C44609 |
SAB |
100ul |
EUR 397 |
 Antibody) Polyclonal Goat Anti-GOT2 (aa 295 to 306) Antibody |
|
AMM04997G |
Leading Biology |
0.1 mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-GOT2 (aa 295 to 306) . This antibody is tested and proven to work in the following applications: |
 Antibody) Polyclonal Goat Anti-GOT2 (aa 360 to 373) Antibody |
|
AMM04998G |
Leading Biology |
0.1 mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-GOT2 (aa 360 to 373) . This antibody is tested and proven to work in the following applications: |
 Antibody) Polyclonal Goat Anti-Renalase (aa 134 to 147) Antibody |
|
AMM05956G |
Leading Biology |
0.1 mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-Renalase (aa 134 to 147) . This antibody is tested and proven to work in the following applications: |
 Antibody) Polyclonal Goat Anti-Renalase (aa 224 to 233) Antibody |
|
APG03367G |
Leading Biology |
0.1 mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-Renalase (aa 224 to 233) . This antibody is tested and proven to work in the following applications: |
 Fgf21 Antibody, HRP conjugated |
|
1-CSB-PA008627LB01MO |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against Fgf21. Recognizes Fgf21 from Mouse. This antibody is HRP conjugated. Tested in the following application: ELISA |
 Fgf21 Antibody, FITC conjugated |
|
1-CSB-PA008627LC01MO |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against Fgf21. Recognizes Fgf21 from Mouse. This antibody is FITC conjugated. Tested in the following application: ELISA |
 Fgf21 Antibody, Biotin conjugated |
|
1-CSB-PA008627LD01MO |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against Fgf21. Recognizes Fgf21 from Mouse. This antibody is Biotin conjugated. Tested in the following application: ELISA |
 FGF21 Antibody, HRP conjugated |
|
1-CSB-PA06404B0Rb |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against FGF21. Recognizes FGF21 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
 FGF21 Antibody, FITC conjugated |
|
1-CSB-PA06404C0Rb |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against FGF21. Recognizes FGF21 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
 FGF21 Antibody, Biotin conjugated |
|
1-CSB-PA06404D0Rb |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against FGF21. Recognizes FGF21 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
 FGF21 recombinant monoclonal antibody |
|
A5710 |
Bimake |
100ul X 3 |
EUR 595 |
|
|
|
Description: A recombinant monoclonal antibody from rabbit against human FGF21 for WB ,ELISA |
 Rabbit Polyclonal Antibody to Human TDP1 |
|
TG2016 |
TopoGen |
250 units |
EUR 414 |
) Polyclonal TRAF3IP2 Antibody (C or N-Term) |
|
AMM08309G |
Leading Biology |
0.1 mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human TRAF3IP2 (C or N-Term). This antibody is tested and proven to work in the following applications: |
 Antibody) Polyclonal Goat Anti-EPB41L2 / 4.1G (aa 593 to 604) Antibody |
|
APG00100G |
Leading Biology |
0.1mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-EPB41L2 / 4.1G (aa 593 to 604) . This antibody is tested and proven to work in the following applications: |
 Antibody) Polyclonal Goat Anti-TUSC4 / NPRL2 (aa 140 to 151) Antibody |
|
APG00353G |
Leading Biology |
0.1mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-TUSC4 / NPRL2 (aa 140 to 151) . This antibody is tested and proven to work in the following applications: |
 Antibody) Polyclonal Goat Anti-BDH2 / DHRS6 (aa 60 to 71) Antibody |
|
AMM04910G |
Leading Biology |
0.1 mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-BDH2 / DHRS6 (aa 60 to 71) . This antibody is tested and proven to work in the following applications: |
 Antibody) Polyclonal Goat Anti-C2GnT-M (aa 273 to 284) Antibody |
|
APR16228G |
Leading Biology |
0.1 mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-C2GnT-M (aa 273 to 284) . This antibody is tested and proven to work in the following applications: |
 Antibody) Polyclonal Goat Anti-C2GnT-M (aa 410 to 422) Antibody |
|
APR16229G |
Leading Biology |
0.1 mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-C2GnT-M (aa 410 to 422) . This antibody is tested and proven to work in the following applications: |
Experimental outcomes on two benchmark knowledgeunits reveal that the proposed MMD-VAE mannequin achieves encouraging predictive efficiency (AUC:0.9939) on a public knowledgeset, and good generalization efficiency (AUC:0.9611) on a cross-institutional personal knowledgeset. These quantitative outcomes and interpretations could assist radiologists perceive gliomas higher and make higher therapy selections for bettering medical outcomes.
